av Gerbrand Koster | mar 7, 2022
Business opportunity Monoclonal antibodies have revolutionized treatment, especially for cancer and autoimmune diseases. However, a full cure of disease is often not achieved. Most approved antibodies are of the IgG1 subclass, which has a long plasma half-life and...
av Aina Rengmark | nov 12, 2021
Business opportunity Scientists from Oslo University Hospital and University of Oslo observed that Vastiras (VAS), a cardiac hormone recombinant-peptide with known beneficial effects on the kidney, has therapeutic effects on the heart in two distinct animal models of...
av Eirik A. Torheim | jun 23, 2021
Our team at Oslo University Hospital and University of Oslo has developed a novel targeting sequence that allows for direct targeting of vaccine antigens to immune cells, thereby improving the immunogenicity and efficacy of subunit vaccines. While the technology can...
av Mika Falck-Hansen | des 15, 2020
Business opportunity The present technology has the potential to effectively treat children and adults with metastatic osteosarcoma (bone cancer) where the disease has progressed beyond the first and second line treatment. Inven2 seeks collaboration with industrial...
av Kim Larsen | jun 29, 2020
Business opportunity Inventors at the University of Oslo/Oslo University Hospital have developed an engineered human albumin variant with extended in vivo half-life. This unique albumin can be used as a fusion partner to improve the pharmacokinetics of...
